跳到正文
← 返回论文列表与筛选
阅读说明

本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。

DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。

引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。

关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。

分类依据与纠错

AI 根据所提供的论文材料归类:摘要研究个体化处理剂量规则及观察性研究中的价值函数学习。

反馈分类问题

正在核对关联版本…

代码、数据与补充材料

正在核对对应版本的资源…

关注这篇论文的作者
Wenzhuo Zhou
Ruoqing Zhu
Donglin Zeng

通过降维构建简约的个性化剂量探索模型

研究问题
如何在高维协变量下学习个体化剂量规则,减少非参数决策估计的维数负担,并评价所得规则的价值?
方法与思路
作者把剂量规则限制在少数协变量线性组合张成的子空间,提出直接与伪直接学习,并用 Stiefel 流形约束优化。
材料陈述的贡献
摘要称直接最大化价值函数无需逆倾向权重,并建立参数渐近正态性及估计剂量规则价值的一致性和收敛速度。
阅读关注点
应核对观察性数据下的因果识别条件、低维子空间假设、维数选择,以及无需逆倾向权重与价值估计的关系。
阅读边界
仅据所给 Crossref 版本摘要,无需逆倾向权重不等于无需混杂控制或重叠条件;具体识别与正则条件未说明。

原文摘要

Summary Learning an individualized dose rule in personalized medicine is a challenging statistical problem. Existing methods often suffer from the curse of dimensionality, especially when the decision function is estimated nonparametrically. To tackle this problem, we propose a dimension reduction framework that effectively reduces the estimation to an optimization on a lower-dimensional subspace of the covariates. We exploit the fact that the individualized dose rule can be defined in a subspace spanned by a few linear combinations of the covariates to obtain a more parsimonious model. Owing to direct maximization of the value function, the proposed framework does not require the inverse probability of the propensity score under observational studies. This distinguishes our approach from the outcome-weighted learning framework, which also solves decision rules directly. Within the same framework, we further propose a pseudo-direct learning approach that focuses more on estimating the dimensionality-reduced subspace of the treatment outcome. Parameters in both approaches can be estimated efficiently using an orthogonality-constrained optimization algorithm on the Stiefel manifold. Under mild regularity assumptions, results on the asymptotic normality of the proposed estimators are established. We also derive the consistency and convergence rate of the value function under the estimated optimal dose rule. We evaluate the performance of the proposed approaches through extensive simulation studies and analysis of a pharmacogenetic dataset.

笔记与分组
相关领域论文